Table 1.

Baseline characteristics of the study population

Age [mean in years (SD)]	39 (16)
Male gender [n (%)]	24 (51.1)
Active smoking [n (%)]	3 (1.3)
On adalimumab (vs. infliximab) [n (%)]	28 (59.6)
Previous exposure to more than one anti-TNF [n (%)]	20 (42.6)
Patients receiving steroids [n (%)]	6 (12.8)
Patients receiving combination therapy with immunomodulators [n (%)]	20 (42.6)
C-Reactive Protein [median in mg/L (IQR)]	1.7 (0.7–5.3)
Patients with active endoscopic disease [n (%)]	22 (46.8)
Crohn’s Disease Phenotype
Ileal disease [n (%)]	15 (31.9)
Ileo-colonic disease [n (%)]	13 (27.7)
Colonic disease [n (%)]	10 (21.3)
Fibro-stenotic disease [n (%)]	21 (44.7)
Internal penetrating/perforating disease [n (%)]	12 (25.5)
Peri-anal disease [n (%)]	20 (42.6)